SCHEMBL206157

SCHEMBL206157

Cc1cccc(CC2(N(C)C)CCC(NC(=O)CCC(=O)N(C)Cc3ccccc3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 6/20 0.44
OPRM1 P35372 2/20 0.43
OPRL1 P41146 2/20 0.43
SSTR1 P30872 1/20 0.43
SSTR4 P31391 1/20 0.43
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 3/20 0.40
HTT P42858 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075132 0.90 SSTR4 (0.43) KMT2AOPRM1OPRL1SSTR1SSTR4
SCHEMBL204623 0.90 KMT2A (0.48) NPC1KMT2AOPRM1OPRL1SSTR1
SCHEMBL205653 0.90 SIGMAR1 (0.48) NPC1RAB9AKMT2AOPRM1OPRL1
SCHEMBL207235 0.88 KMT2A (0.47) KMT2AOPRM1OPRL1SSTR1SSTR4
SCHEMBL207003 0.87 KMT2A (0.39) KMT2AOPRM1OPRL1SSTR1SSTR4
SCHEMBL4052851 0.86 KMT2A (0.48) NPC1RAB9AKMT2AOPRM1OPRL1
SCHEMBL206665 0.85 SSTR4 (0.45) NPC1RAB9AKMT2AOPRM1OPRL1
SCHEMBL206736 0.85 HPGD (0.48) NPC1RAB9AKMT2AOPRM1OPRL1
SCHEMBL4073100 0.84 SSTR1 (0.39) KMT2AOPRM1OPRL1SSTR1SSTR4
SCHEMBL5157976 0.83 SSTR4 (0.45) NPC1KMT2AOPRM1OPRL1SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD NPC1 46/4885RAB9A 587/4885KMT2A 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.